Malaria Drug Combo Cures 7 of 7 Babesiosis Patients

All seven patients with relapsing babesiosis walked away cured after receiving an experimental treatment combining tafenoquine with standard medications.

The results come from 60 Degrees Pharmaceuticals, which treated three immunosuppressed patients in an expanded-use trial. When combined with earlier data from four Yale patients, every single person achieved full recovery. For context, babesiosis is a tick-borne parasite infection that can become chronic in people with weakened immune systems, lasting months or even years despite standard treatment.

The winning combination added weekly doses of tafenoquine, currently FDA-approved for malaria prevention, to existing babesiosis medications containing atovaquone. Patients stayed on the regimen until two consecutive PCR tests came back negative, sometimes taking up to a year. After stopping treatment, all patients remained disease-free during 60 to 90 days of follow-up monitoring.

What makes these results particularly meaningful is who they helped. All patients had immunosuppression, the very group most vulnerable to relapsing babesiosis and hardest to cure with current treatments. Before this trial, these individuals faced cycles of illness and medication without clear resolution.

The research team used highly sensitive FDA-approved RNA testing that can detect the parasite at levels 1,000 times lower than standard tests. This precision gives confidence that patients are truly cured, not just showing temporary improvement.

Why This Inspires

Babesiosis has been spreading across the United States as tick populations expand their range. What was once concentrated in the Northeast now affects people in states that never worried about this infection before. Thousands of Americans develop babesiosis each year, and for those with cancer, organ transplants, or other immune challenges, finding an effective cure has been desperately needed.

This small trial represents the kind of medical progress that changes individual lives immediately while paving the way for broader solutions. Seven people who faced ongoing illness now have their health back. The path forward involves larger Phase 2 trials at major medical centers including Mount Sinai and Brigham and Women's Hospital.

While tafenoquine isn't yet approved for babesiosis treatment, the perfect cure rate across all patients suggests researchers may have found the missing piece in treating this challenging infection.

For thousands living with chronic babesiosis, these seven success stories light the way toward lasting relief.